Background
Cytokine Release Syndrome (CRS) is a well-recognized toxicity that occurs with high frequency following treatments such as T-cell engaging antibodies, Chimeric Antigen Receptor (CAR) T cells and other T-cell boosting immunotherapies. In addition to patient mortality and morbidity, the high frequency of CRS associated with these treatments represents a barrier to delivery in the outpatient setting. The need for inpatient management of CRS adds to the costs of these treatments and contributes to restricting their availability. Current treatments are dominated by reactive administration of tocilizumab, steroids or anakinra. POLB 001 is a p38 MAPK inhibitor in development for severe influenza infections and CRS. In vivo, POLB 001 acts as a broad-spectrum anti-inflammatory by potently inhibiting the expression of proinflammatory cytokines such as IL-1β, IL-6, IL-8, IL-10, TNFα, COX-2.
Poolbeg Pharma plc (LON:POLB) is a clinical stage infectious disease pharmaceutical company, with a novel capital light clinical model which enables us to develop multiple products faster and more cost effectively than the traditional biotech model.
